442852-08-6

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 177898-40-7 N-octyl-2,3:4,6-di-O-isopropylidene-5a-carba-β-D-xylo-hex-5(5a)-enopyranosylamine 
• 442851-92-5 N-octyl-N-tert-butoxycarbonyl-2,3:4,6-di-O-isopropylidene-5a-carba-β-D-xylo-hex-5(5a)-enopyranosylamine 

Downstream Products

• 442852-02-0 N-octyl-N-tert-butoxycarbonyl-2,3-di-O-methoxymethyl-6-O-tert-butyldimethylsilyl-5a-carba-α-L-arabino-hex-5(5a)-enopyranosylamine 
• 442852-00-8 N-octyl-N-tert-butoxycarbonyl-2,3-di-O-methoxymethyl-6-O-tert-butyldimethylsilyl-5a-carba-β-D-xylo-hex-5(5a)-enopyranosylamine 
• 442851-98-1 N-octyl-N-tert-butoxycarbonyl-4,6-O-benzylidene-2,3-di-O-methoxymethyl-5a-carba-β-D-xylo-hex-5(5a)-enopyranosylamine 
• 442851-96-9 N-octyl-N-tert-butoxycarbonyl-4,6-O-benzylidene-5a-carba-β-D-xylo-hex-5(5a)-enopyranosylamine 
• 442852-10-0 N-octyl-N-tert-butoxycarbonyl-2,3-di-O-methoxymethyl-5a-carba-β-D-xylo-hexo-5(5a)-enopyranosylamine 
• 442851-90-3 (1R,2S,3S,4S)-5-hydroxymethyl-1-octylamino-2,3,4-trihydroxycyclohex-5-ene 
• 442852-09-7 ((3aS,4R,9aR,9bS)-2,8-Diphenyl-4,6,9a,9b-tetrahydro-3aH-[1,3]dioxolo[4',5':3,4]benzo[1,2-d][1,3]dioxin-4-yl)-octyl-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

CARBA-SUGAR AMINE DERIVATIVES AND TREATMENTS FOR DISORDER OF GLYCOLIPID METABOLISM CONTAINING THE SAME AS THE ACTIVE INGREDIENT

A carba-sugar amine derivative represented by the following formula (1) or (2) is used as the active ingredient of a β-galactosidase inhibitor or a glycolipid metabolic disorder treating agent. Wherein each of R1 and R2 independently

Chemical modification of the beta-glucocerebrosidase inhibitor N-octyl-beta-valienamine: synthesis and biological evaluation of 4-epimeric and 4-O-(beta-D-galactopyranosyl) derivatives.

N-Octyl-beta-valienemine (1), a potent beta-glucocerebrosidase inhibitor, was chemically transformed into two biologically interesting compounds: the 4-epimer, beta-galacto-type N-octyl-valienamine, and the 4-O-(beta-D-galactopyranosyl) derivative, a carba-lactosylceramide analogue. The former, interestingly, could be demonstrated to act as a very effective inhibitor (IC(50)=0.3 microM) of human beta-galactosidase. The latter exhibited moderate inhibitory activity (IC(50)=20 microM) against beta-glucocerebrosidase (mouse liver).